Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management
Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-on...
Gespeichert in:
Veröffentlicht in: | Drugs & aging 2024-09, Vol.41 (9), p.713-724 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 724 |
---|---|
container_issue | 9 |
container_start_page | 713 |
container_title | Drugs & aging |
container_volume | 41 |
creator | Tada, Yoshifumi Maruyama, Akihito Shirahama, Yuri |
description | Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients. |
doi_str_mv | 10.1007/s40266-024-01137-6 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3087699406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3087699406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-b89beedb0ea0b99eb7f320eed193e75956e8ff635bd1eb67423dc680734e310c3</originalsourceid><addsrcrecordid>eNp9kM1O3DAQxy1UVL76AhyqSL1wIDC2EzvuDS0fRQLtga7Um-Ukk1WQ16Ge5MCtr9HX40kw7EKlHjh55PnNf0Y_xg45nHAAfUoFCKVyEEUOnEudqy22y7k2OTfKfHqtIRfC_Nphe0T3AKCE4J_ZjjRgdCnLXba4G3vvn_78pey8J3SE2TwQjlkfsrlvMWZn7eRH-p7NfB_6xvnsEt04RaTjNOGWYaA-lS602a0LbokrDOMB2-6cJ_yyeffZ4vLi5-xHfjO_up6d3eSNFGrM68rUiG0N6KA2BmvdSQHphxuJujSlwqrrlCzrlmOtdCFk26gKtCxQcmjkPjta5z7E4feENNpVTw167wIOE1kJlVbGFKAS-u0_9H6YYkjX2RRVVbzUWidKrKkmDkQRO_sQ-5WLj5aDfZFu19Jtkm5fpduX6K-b6KleYfs-8mY5AXINUGqFJcZ_uz-IfQbehIx-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3108815777</pqid></control><display><type>article</type><title>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Tada, Yoshifumi ; Maruyama, Akihito ; Shirahama, Yuri</creator><creatorcontrib>Tada, Yoshifumi ; Maruyama, Akihito ; Shirahama, Yuri</creatorcontrib><description>Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients.</description><identifier>ISSN: 1170-229X</identifier><identifier>ISSN: 1179-1969</identifier><identifier>EISSN: 1179-1969</identifier><identifier>DOI: 10.1007/s40266-024-01137-6</identifier><identifier>PMID: 39097535</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aged ; Arthritis ; Biological products ; Biomarkers ; Case reports ; Clinical outcomes ; Cluster analysis ; Cytokines ; Dehydrogenases ; Fever ; Geriatrics/Gerontology ; Humans ; Immunosuppressive agents ; Inflammation ; Inflammatory diseases ; Internal Medicine ; Laboratories ; Medical diagnosis ; Medical prognosis ; Medical treatment ; Medicine ; Medicine & Public Health ; Mortality ; Older people ; Pharmacology/Toxicology ; Pharmacotherapy ; Pulmonary embolisms ; Review Article ; Still's Disease, Adult-Onset - diagnosis ; Still's Disease, Adult-Onset - drug therapy ; Still's Disease, Adult-Onset - therapy ; Young adults</subject><ispartof>Drugs & aging, 2024-09, Vol.41 (9), p.713-724</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>Copyright Springer Nature B.V. Sep 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-b89beedb0ea0b99eb7f320eed193e75956e8ff635bd1eb67423dc680734e310c3</cites><orcidid>0000-0003-0742-831X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40266-024-01137-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40266-024-01137-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39097535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tada, Yoshifumi</creatorcontrib><creatorcontrib>Maruyama, Akihito</creatorcontrib><creatorcontrib>Shirahama, Yuri</creatorcontrib><title>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</title><title>Drugs & aging</title><addtitle>Drugs Aging</addtitle><addtitle>Drugs Aging</addtitle><description>Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients.</description><subject>Aged</subject><subject>Arthritis</subject><subject>Biological products</subject><subject>Biomarkers</subject><subject>Case reports</subject><subject>Clinical outcomes</subject><subject>Cluster analysis</subject><subject>Cytokines</subject><subject>Dehydrogenases</subject><subject>Fever</subject><subject>Geriatrics/Gerontology</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Internal Medicine</subject><subject>Laboratories</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Older people</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Pulmonary embolisms</subject><subject>Review Article</subject><subject>Still's Disease, Adult-Onset - diagnosis</subject><subject>Still's Disease, Adult-Onset - drug therapy</subject><subject>Still's Disease, Adult-Onset - therapy</subject><subject>Young adults</subject><issn>1170-229X</issn><issn>1179-1969</issn><issn>1179-1969</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1O3DAQxy1UVL76AhyqSL1wIDC2EzvuDS0fRQLtga7Um-Ukk1WQ16Ge5MCtr9HX40kw7EKlHjh55PnNf0Y_xg45nHAAfUoFCKVyEEUOnEudqy22y7k2OTfKfHqtIRfC_Nphe0T3AKCE4J_ZjjRgdCnLXba4G3vvn_78pey8J3SE2TwQjlkfsrlvMWZn7eRH-p7NfB_6xvnsEt04RaTjNOGWYaA-lS602a0LbokrDOMB2-6cJ_yyeffZ4vLi5-xHfjO_up6d3eSNFGrM68rUiG0N6KA2BmvdSQHphxuJujSlwqrrlCzrlmOtdCFk26gKtCxQcmjkPjta5z7E4feENNpVTw167wIOE1kJlVbGFKAS-u0_9H6YYkjX2RRVVbzUWidKrKkmDkQRO_sQ-5WLj5aDfZFu19Jtkm5fpduX6K-b6KleYfs-8mY5AXINUGqFJcZ_uz-IfQbehIx-</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Tada, Yoshifumi</creator><creator>Maruyama, Akihito</creator><creator>Shirahama, Yuri</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0742-831X</orcidid></search><sort><creationdate>20240901</creationdate><title>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</title><author>Tada, Yoshifumi ; Maruyama, Akihito ; Shirahama, Yuri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-b89beedb0ea0b99eb7f320eed193e75956e8ff635bd1eb67423dc680734e310c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Arthritis</topic><topic>Biological products</topic><topic>Biomarkers</topic><topic>Case reports</topic><topic>Clinical outcomes</topic><topic>Cluster analysis</topic><topic>Cytokines</topic><topic>Dehydrogenases</topic><topic>Fever</topic><topic>Geriatrics/Gerontology</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Internal Medicine</topic><topic>Laboratories</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Older people</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Pulmonary embolisms</topic><topic>Review Article</topic><topic>Still's Disease, Adult-Onset - diagnosis</topic><topic>Still's Disease, Adult-Onset - drug therapy</topic><topic>Still's Disease, Adult-Onset - therapy</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tada, Yoshifumi</creatorcontrib><creatorcontrib>Maruyama, Akihito</creatorcontrib><creatorcontrib>Shirahama, Yuri</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs & aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tada, Yoshifumi</au><au>Maruyama, Akihito</au><au>Shirahama, Yuri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</atitle><jtitle>Drugs & aging</jtitle><stitle>Drugs Aging</stitle><addtitle>Drugs Aging</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>41</volume><issue>9</issue><spage>713</spage><epage>724</epage><pages>713-724</pages><issn>1170-229X</issn><issn>1179-1969</issn><eissn>1179-1969</eissn><abstract>Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39097535</pmid><doi>10.1007/s40266-024-01137-6</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0742-831X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1170-229X |
ispartof | Drugs & aging, 2024-09, Vol.41 (9), p.713-724 |
issn | 1170-229X 1179-1969 1179-1969 |
language | eng |
recordid | cdi_proquest_miscellaneous_3087699406 |
source | MEDLINE; SpringerLink Journals |
subjects | Aged Arthritis Biological products Biomarkers Case reports Clinical outcomes Cluster analysis Cytokines Dehydrogenases Fever Geriatrics/Gerontology Humans Immunosuppressive agents Inflammation Inflammatory diseases Internal Medicine Laboratories Medical diagnosis Medical prognosis Medical treatment Medicine Medicine & Public Health Mortality Older people Pharmacology/Toxicology Pharmacotherapy Pulmonary embolisms Review Article Still's Disease, Adult-Onset - diagnosis Still's Disease, Adult-Onset - drug therapy Still's Disease, Adult-Onset - therapy Young adults |
title | Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A01%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Still%E2%80%99s%20Disease%20Onset%20in%20Older%20Adults:%20Clinical%20Features,%20Diagnosis,%20and%20Management&rft.jtitle=Drugs%20&%20aging&rft.au=Tada,%20Yoshifumi&rft.date=2024-09-01&rft.volume=41&rft.issue=9&rft.spage=713&rft.epage=724&rft.pages=713-724&rft.issn=1170-229X&rft.eissn=1179-1969&rft_id=info:doi/10.1007/s40266-024-01137-6&rft_dat=%3Cproquest_cross%3E3087699406%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3108815777&rft_id=info:pmid/39097535&rfr_iscdi=true |